Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
NASDAQ:TBPH
Theravance Biopharma (TBPH) Stock Price & Analysis
310 Followers
TBPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.13 - $11.71
Previous Close$8.76
Volume209.46K
Average Volume (3M)389.19K
Market Cap
$426.03M
Enterprise Value$373.96M
Total Cash (Recent Filing)$99.97M
Total Debt (Recent Filing)$47.90M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Jul 31, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding48,633,224
10 Day Avg. Volume296,881
30 Day Avg. Volume389,190
Standard Deviation0.14
R-Squared0.00848
Alpha-0.00483
Financial Highlights & Ratios
Price to Book (P/B)2.08
Price to Sales (P/S)7.41
Price to Cash Flow (P/CF)-104.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.08
Enterprise Value/Gross Profit6.51
Enterprise Value/Ebitda-43.51
Forecast
1Y Price Target
$16.50Price Target Upside88.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Theravance Biopharma News
PremiumPre-Earnings
Is TBPH a Buy, Before Earnings?
PremiumCompany Announcements
A New Cause for Concern: Theravance Biopharma Adds a New Costs Risk
Bulls Say, Bears Say
Bulls Say
DifferentiationAmpreloxetine represents a differentiated mechanism of action compared to midodrine and droxidopa.
Market PotentialAmpreloxetine's ability to address one of MSA's limiting symptoms indicates its significant market potential.
MilestonesTrelegy's global net sales were $749M, a 32% YoY increase, and Theravance is likely to make a $25 million milestone for Trelegy, reaching $2.9B in 2024.
Bears Say
Drug EfficacyAmpreloxetine will have no effect on MSA progression.
Market OpportunitiesMarket opportunities of ampreloxetine in MSA nOH can be hard to pinpoint as literature estimates for rare diseases have been inconsistent.
Treatment EffectivenessTwo commonly used treatments, midodrine and droxidopa, can only provide limited benefits.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TBPH FAQ
What was Theravance Biopharma’s price range in the past 12 months?
Theravance Biopharma lowest stock price was $8.13 and its highest was $11.71 in the past 12 months.
What is Theravance Biopharma’s market cap?
Currently, no data Available
When is Theravance Biopharma’s upcoming earnings report date?
Theravance Biopharma’s upcoming earnings report date is Jul 31, 2024 which is in 24 days.
How were Theravance Biopharma’s earnings last quarter?
Theravance Biopharma released its earnings results on May 13, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.012.
Is Theravance Biopharma overvalued?
According to Wall Street analysts Theravance Biopharma’s price is currently Undervalued.
Does Theravance Biopharma pay dividends?
Theravance Biopharma does not currently pay dividends.
What is Theravance Biopharma’s EPS estimate?
Theravance Biopharma’s EPS estimate is -$0.21.
How many shares outstanding does Theravance Biopharma have?
Theravance Biopharma has 48,633,224 shares outstanding.
What happened to Theravance Biopharma’s price movement after its last earnings report?
Theravance Biopharma reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went down -1.983%.
Which hedge fund is a major shareholder of Theravance Biopharma?
Among the largest hedge funds holding Theravance Biopharma’s share is Baupost Group LLC. It holds Theravance Biopharma’s shares valued at 59M.
---
Theravance Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.50 (88.36% Upside)
$16.50 (88.36% Upside)
Blogger Sentiment
Bullish
TBPH Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 975.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.60%
12-Months-Change
Fundamentals
Return on Equity
-15.56%
Trailing 12-Months
Asset Growth
-31.05%
Trailing 12-Months
Company Description
Theravance Biopharma
Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
---
TBPH Stock 12 Month Forecast
Average Price Target
$16.50
▲(88.36% Upside)
Technical Analysis
Best Analysts Covering TBPH
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-2.74%
reiterated a buy rating 2 months ago
Copying David Risinger's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -2.74% per trade.
---